AGC Biologics’ Longmont GM joins Colorado BioScience Association board
LONGMONT — Tony Fraij, general manager of AGC Biologics Inc.’s plant in Longmont, has been appointed to the Colorado Bioscience Association’s board of directors.
“Thirty board members representing medical device and diagnostics, pharmaceuticals, ag bio and animal health, digital health, academic and research institutions, and service providers make up the CBSA board,” according to a company news release.
Fraij was hired to lead the new AGC manufacturing facility at 4000 Nelson Road in August 2021.
SPONSORED CONTENT
How dispatchable resources enable the clean energy transition
Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).
“I’m honored to have been asked to join CBSA’s board of directors,” Fraij said in a prepared statement. “I very much look forward to supporting the advancement of the life sciences in Colorado — especially the emerging cell and gene therapy community — in partnership with the other board members, Elyse Blazevich, CBSA president and CEO, and the countless members of this talented community.”
AGC bought the six-building, 692,000-square-foot Longmont manufacturing campus last summer from Novartis AG (NYSE: NVS) gene therapy subsidiary AveXis for $36 million.
AGC is a relatively new player on Boulder County’s biosciences scene, acquiring AstraZeneca’s Boulder plant for $39.7 million in 2020.
In addition to the new operation in Longmont, the company plans to expand the 178,000-square-foot Boulder facility by 126,000 square feet.
